Evaluation of mixed microalgae species biorefinery of Desmodesmus sp. And Scenedesmus sp. For bioproducts synthesis

Microalgae is known to produce numerous bioactive compounds for instance proteins, fatty acid, polysaccharides, enzymes, sterols, and antioxidants. Due to their valuable biochemical composition, microalgae are regarded as a very intriguing source to produce novel food products and can be utilised to improve the nutritional content of traditional foods. Additionally, microalgae are used as animal feed and additives in the cosmetics, pharmaceutical as well as nutraceutical industries. As compared to other terrestrial plants and other microorganisms, microalgae possess few advantages: (1) rapid growth rate; (2) able to grow in non-arable land and harsh cultivation conditions; (3) low nutritional requirements; (4) high productivity; and (5) reduce emission of carbon dioxide. Despite the large number of microalgae species found in nature, only a few species are identified and commercialized such as Chlorella sp., Spirulina sp. Haematococcus pluvialis, Nannochloropsis sp. and Chlamydomonas reinhardtii, which is one of the major obstacles preventing the full utilisation of microalgae-based technology. This thesis provides information on the overall composition of mixed microalgae species, Desmodesmus sp. and Scenedesmus sp., for instance protein, carbohydrate, lipid, antioxidants, and pigment. This thesis firstly introduces the application of triphasic partitioning (TPP) in the extraction and partitioning of the biomolecules from the microalgae. The latest advancement of technology has evolved from a liquid biphasic flotation (LBF) to TPP. T-butanol and ammonium sulphate are used in TPP to precipitate desired biomolecules from the aqueous solutions with the formation of three layer. TPP is a simple, time- and cost- efficient, as well as scalable process that does not require toxic organic solvents. Lipase is abundantly produced by microbes, bacteria, fungi, yeast, mammals, and plants. Lipase is widely used in the oleochemical, detergent, dairy, leather, cosmetics, paper, cosmetics, and nutraceutical industries. Therefore, this thesis also discusses the possibility of identifying and extracting enzyme lipase from the microalgae using LBF. Several parameters (volume and concentration of solvents, weight of biomass, flotation kinetics and solvent types, etc.) have been investigated to optimize the lipase extraction from LBF. Chlorophyll is the main pigment present in the microalgae. Thus, this work proposes the digital imaging approach to determine the chlorophyll concentration in the microalgae rapidly because the chlorophyll content has a significant impact on microalgae physiological health status as well as identifies the chlorophyll concentration in the production of by-products. Lastly, microalgae oil can be used as the feedstock for biodiesel as well as nutraceutical, pharmaceutical, and health-care products. The challenge in the lipid extraction is the co-extraction of chlorophyll into the oil, which can have serious consequences for downstream processing. Therefore, the removal of the chlorophyll from the microalgae using activated clay or sodium chlorite in the pre-treatment procedure are examined. The research achievements in these works and future opportunities are highlighted in the last chapter of the thesis

Evaluation of mixed microalgae species biorefinery of Desmodesmus sp. And Scenedesmus sp. For bioproducts synthesis

Microalgae is known to produce numerous bioactive compounds for instance proteins, fatty acid, polysaccharides, enzymes, sterols, and antioxidants. Due to their valuable biochemical composition, microalgae are regarded as a very intriguing source to produce novel food products and can be utilised to improve the nutritional content of traditional foods. Additionally, microalgae are used as animal feed and additives in the cosmetics, pharmaceutical as well as nutraceutical industries. As compared to other terrestrial plants and other microorganisms, microalgae possess few advantages: (1) rapid growth rate; (2) able to grow in non-arable land and harsh cultivation conditions; (3) low nutritional requirements; (4) high productivity; and (5) reduce emission of carbon dioxide. Despite the large number of microalgae species found in nature, only a few species are identified and commercialized such as Chlorella sp., Spirulina sp. Haematococcus pluvialis, Nannochloropsis sp. and Chlamydomonas reinhardtii, which is one of the major obstacles preventing the full utilisation of microalgae-based technology. This thesis provides information on the overall composition of mixed microalgae species, Desmodesmus sp. and Scenedesmus sp., for instance protein, carbohydrate, lipid, antioxidants, and pigment. This thesis firstly introduces the application of triphasic partitioning (TPP) in the extraction and partitioning of the biomolecules from the microalgae. The latest advancement of technology has evolved from a liquid biphasic flotation (LBF) to TPP. T-butanol and ammonium sulphate are used in TPP to precipitate desired biomolecules from the aqueous solutions with the formation of three layer. TPP is a simple, time- and cost- efficient, as well as scalable process that does not require toxic organic solvents. Lipase is abundantly produced by microbes, bacteria, fungi, yeast, mammals, and plants. Lipase is widely used in the oleochemical, detergent, dairy, leather, cosmetics, paper, cosmetics, and nutraceutical industries. Therefore, this thesis also discusses the possibility of identifying and extracting enzyme lipase from the microalgae using LBF. Several parameters (volume and concentration of solvents, weight of biomass, flotation kinetics and solvent types, etc.) have been investigated to optimize the lipase extraction from LBF. Chlorophyll is the main pigment present in the microalgae. Thus, this work proposes the digital imaging approach to determine the chlorophyll concentration in the microalgae rapidly because the chlorophyll content has a significant impact on microalgae physiological health status as well as identifies the chlorophyll concentration in the production of by-products. Lastly, microalgae oil can be used as the feedstock for biodiesel as well as nutraceutical, pharmaceutical, and health-care products. The challenge in the lipid extraction is the co-extraction of chlorophyll into the oil, which can have serious consequences for downstream processing. Therefore, the removal of the chlorophyll from the microalgae using activated clay or sodium chlorite in the pre-treatment procedure are examined. The research achievements in these works and future opportunities are highlighted in the last chapter of the thesis

Climate-Conscious Food Preserving Technologies for Food Waste Prevention

Global food production is responsible for around 26% of greenhouse gas emissions caused by human activities. Notably, 6% of these emissions are caused by unconsumed food. Both traditional and current climate-conscious technologies for food preservatives that assure food waste reduction are discussed. This review investigates the potential of smart packaging biosensors and natural antimicrobial agents in fostering environmentally friendly, cutting-edge food systems. Specifically, it highlights the studies that explore the use of natural antimicrobial agents of calcined corals in active packaging systems for storing milk. The finding revealed that this method had a significant impact on maximizing the shelf life of fresh food. Furthermore, this review discusses the concept of smart packaging of food, focusing on biopolymer-based nanocomposites and biosensors, which have gained increasing attention in the food industry due to concerns about food safety and quality. The review also examines the efforts of the United Arab Emirates (UAE) to combat food waste through the initiatives such as UAE Food Bank, Winnow, and Ne’ma which is the national food loss and waste project. These technologies and practices have the potential to guarantee food safety, preserve quality, and reduce waste, but there are still issues with cost, biocompatibility, and consumer acceptance

Activation of epidermal growth factor receptor is required for Chlamydia trachomatis development

Background Chlamydia trachomatis (C. trachomatis) is a clinically significant human pathogen and one of the leading causative agents of sexually transmitted diseases. As obligate intracellular bacteria, C. trachomatis has evolved strategies to redirect the host’s signaling and resources for its own survival and propagation. Despite the clinical notoriety of Chlamydia infections, the molecular interactions between C. trachomatis and its host cell proteins remain elusive. Results In this study, we focused on the involvement of the host cell epidermal growth factor receptor (EGFR) in C. trachomatis attachment and development. A combination of molecular approaches, pharmacological agents and cell lines were used to demonstrate distinct functional requirements of EGFR in C. trachomatisinfection. We show that C. trachomatis increases the phosphorylation of EGFR and of its downstream effectors PLCγ1, Akt and STAT5. While both EGFR and platelet-derived growth factor receptor-β (PDGFRβ) are partially involved in bacterial attachment to the host cell surface, it is only the knockdown of EGFR and not PDGFRβ that affects the formation of C. trachomatis inclusions in the host cells. Inhibition of EGFR results in small immature inclusions, and prevents C. trachomatis-induced intracellular calcium mobilization and the assembly of the characteristic F-actin ring at the inclusion periphery. By using complementary approaches, we demonstrate that the coordinated regulation of both calcium mobilization and F-actin assembly by EGFR are necessary for maturation of chlamydial inclusion within the host cells. A particularly important finding of this study is the co-localization of EGFR with the F-actin at the periphery of C. trachomatis inclusion where it may function to nucleate the assembly of signaling protein complexes for cytoskeletal remodeling required for C. trachomatisdevelopment. Conclusion Cumulatively, the data reported here connect the function of EGFR to C. trachomatis attachment and development in the host cells, and this could lead to new venues for targeting C. trachomatis infections and associated diseases

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study

Background: Surgical site infection (SSI) is one of the most common infections associated with health care, but its importance as a global health priority is not fully understood. We quantified the burden of SSI after gastrointestinal surgery in countries in all parts of the world. Methods: This international, prospective, multicentre cohort study included consecutive patients undergoing elective or emergency gastrointestinal resection within 2-week time periods at any health-care facility in any country. Countries with participating centres were stratified into high-income, middle-income, and low-income groups according to the UN's Human Development Index (HDI). Data variables from the GlobalSurg 1 study and other studies that have been found to affect the likelihood of SSI were entered into risk adjustment models. The primary outcome measure was the 30-day SSI incidence (defined by US Centers for Disease Control and Prevention criteria for superficial and deep incisional SSI). Relationships with explanatory variables were examined using Bayesian multilevel logistic regression models. This trial is registered with ClinicalTrials.gov, number NCT02662231. Findings: Between Jan 4, 2016, and July 31, 2016, 13 265 records were submitted for analysis. 12 539 patients from 343 hospitals in 66 countries were included. 7339 (58·5%) patient were from high-HDI countries (193 hospitals in 30 countries), 3918 (31·2%) patients were from middle-HDI countries (82 hospitals in 18 countries), and 1282 (10·2%) patients were from low-HDI countries (68 hospitals in 18 countries). In total, 1538 (12·3%) patients had SSI within 30 days of surgery. The incidence of SSI varied between countries with high (691 [9·4%] of 7339 patients), middle (549 [14·0%] of 3918 patients), and low (298 [23·2%] of 1282) HDI (p < 0·001). The highest SSI incidence in each HDI group was after dirty surgery (102 [17·8%] of 574 patients in high-HDI countries; 74 [31·4%] of 236 patients in middle-HDI countries; 72 [39·8%] of 181 patients in low-HDI countries). Following risk factor adjustment, patients in low-HDI countries were at greatest risk of SSI (adjusted odds ratio 1·60, 95% credible interval 1·05–2·37; p=0·030). 132 (21·6%) of 610 patients with an SSI and a microbiology culture result had an infection that was resistant to the prophylactic antibiotic used. Resistant infections were detected in 49 (16·6%) of 295 patients in high-HDI countries, in 37 (19·8%) of 187 patients in middle-HDI countries, and in 46 (35·9%) of 128 patients in low-HDI countries (p < 0·001). Interpretation: Countries with a low HDI carry a disproportionately greater burden of SSI than countries with a middle or high HDI and might have higher rates of antibiotic resistance. In view of WHO recommendations on SSI prevention that highlight the absence of high-quality interventional research, urgent, pragmatic, randomised trials based in LMICs are needed to assess measures aiming to reduce this preventable complication

Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018 population-based measurement studies with 88.6 million participants

© The Author(s) 2018. Background: Change in the prevalence of raised blood pressure could be due to both shifts in the entire distribution of blood pressure (representing the combined effects of public health interventions and secular trends) and changes in its high-blood-pressure tail (representing successful clinical interventions to control blood pressure in the hypertensive population). Our aim was to quantify the contributions of these two phenomena to the worldwide trends in the prevalence of raised blood pressure. Methods: We pooled 1018 population-based studies with blood pressure measurements on 88.6 million participants from 1985 to 2016. We first calculated mean systolic blood pressure (SBP), mean diastolic blood pressure (DBP) and prevalence of raised blood pressure by sex and 10-year age group from 20-29 years to 70-79 years in each study, taking into account complex survey design and survey sample weights, where relevant. We used a linear mixed effect model to quantify the association between (probittransformed) prevalence of raised blood pressure and age-group- and sex-specific mean blood pressure. We calculated the contributions of change in mean SBP and DBP, and of change in the prevalence-mean association, to the change in prevalence of raised blood pressure. Results: In 2005-16, at the same level of population mean SBP and DBP, men and women in South Asia and in Central Asia, the Middle East and North Africa would have the highest prevalence of raised blood pressure, and men and women in the highincome Asia Pacific and high-income Western regions would have the lowest. In most region-sex-age groups where the prevalence of raised blood pressure declined, one half or more of the decline was due to the decline in mean blood pressure. Where prevalence of raised blood pressure has increased, the change was entirely driven by increasing mean blood pressure, offset partly by the change in the prevalence-mean association. Conclusions: Change in mean blood pressure is the main driver of the worldwide change in the prevalence of raised blood pressure, but change in the high-blood-pressure tail of the distribution has also contributed to the change in prevalence, especially in older age groups

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead